Gastrointestinal Cancer News

An analysis of older individuals who presented to the ED showed those with cancer appeared more likely to be admitted to the hospital, whereas those who were cancer free were more likely to be observed or released home.

Nearly one in five patients with pancreatic cancer and a history of Lynch syndrome-related or hereditary breast or ovarian cancers tested positive for a genetic mutation that made them susceptible to pancreatic cancer, according to recently published findings.

Little evidence exists to support the use of most circulating tumor DNA assays in either early- or late-stage cancer, according to a newly published review by ASCO and College of American Pathologists summarizing clinical validity and utility.

Paul E. Oberstein, MD, has been appointed director of gastrointestinal medical oncology at NYU Langone Health and its Perlmutter Cancer Center.

Elevated levels of blood glucose are linked to an increased risk for a number of cancers, including breast and colorectal cancers.

People living with HIV who are diagnosed with cancer should be offered the same treatment as those without HIV; however, considerations should be made for potential interactions and toxicities, according to new practice guidelines from the National Comprehensive Cancer Network.

The FDA granted fast track designation to pamrevlumab for the treatment of patients with locally advanced unresectable pancreatic cancer, according to a manufacturer-issued press release.

The Stand Up To Cancer foundation has formed a “dream team” to identify new ways to detect pancreatic cancer at earlier stages when it is most amenable to treatment.

Diets with higher nut consumption appeared to be associated with reduced risk for disease recurrence and mortality among patients with stage III colon cancer, according to results from the prospective, observational CALGB 89803 study.

The FDA granted orphan drug designation to YS-ON-001, an immuno-oncology biologic product, for the treatment of pancreatic cancer, according to the agent’s manufacturer.